Atrial fibrillation, stroke and anticoagulation: Under-use of warfarin?;Fibrilação atrial crõnica, AVC e anticoagulaç ão: Sub-uso de warfarina?

Arquivos de Neuro-Psiquiatria

Volumn 62, Issue 4, 2004, Pages 1016-1021

  Cabral, Norberto L ^a,d   Volpato, Dalton ^a   Ogata, Tatiana Rosa ^a   Ramirez, Tenille ^a   Moro, Carla ^b   Gouveia, Sergio ^c  

^a UNIVERSITY OF JOINVILLE REGION   (Brazil)

^b São José Municipal Hospital at Joinville   (Brazil)

^c Hospital Dona Helena   (Brazil)

^d Clinica Neurológica de Joinville   (Brazil)

Author keywords

Anticoagulation; Atrial fibrillation; Stroke prevention; Warfarina

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

AGED; ANTICOAGULATION; ARTICLE; CEREBROVASCULAR ACCIDENT; DEATH; FEMALE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HOSPITAL DISCHARGE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PROSPECTIVE STUDY; STROKE;

EID: 10944263770     PISSN: 0004282X     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0004-282x2004000600016     Document Type: Article

References (27)

1. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution and gender of patients with atrial fibrillation: analysis and implications. Arch Intern Med 1995;155:469-473.
2. Daley R, Mattlingly TW, Holt CL, et al. Systemic arterial embolism in rheumatic heart disease. Am Heart J 1951;42:566-581.
3. a edição. Rio de Janeiro:Guanabara Koogan, 2001:262-270.
4. Benjamin EJ, Wolf PA, D Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998:98:946-952.
5. Cabral NL, Longo ALL, Moro CHC, Amaral CH, Kiss HC. Epidemiologia dos acidentes cerebrovasculares em Joinville, Brasil. Arq Neuropsiquiatr 1997;55:357-363.
6. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor of stroke in the elderly: the Framingham Study. Arch Intern Med 1987;147:1561-1564.
7. Bungard TJ, Ghali WA, Teo KK, Maclister FA, Tsuyuki RT. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 2000;160:41-46.
8. Sudlow M, Thomson R, Thwaites B, Rodgers H, Kenny RA. Prevalence of atrial fibrillation and eligibility for anticoagulation in the community. Lancet 1998;352:1167-171.
9. Connolly SW, Stuart J. Preventing stroke in atrial fibrillation: why are so many eligible patients not receiving anticoagulation therapy? CMAJ.1999;161:533-534.
10. Roderick E, Cox J. Non-valvular atrial fibrillation. Br Gen Pract 1997;47:660-661.
11. Thomson R, Mcelroy H, Sudlow M. Guidelines on anticoagulant treatment in atrial fibrillation in Great Britain: variation and implications for treatment. BMJ 1996;316:509-513.
12. Gottlieb LK, Salem-Schatz S. Ariticoagulation in atrial fibrillation: does efficacy in clinical trials translate into effectiveness in practice? Arch Intern Med 1994;154:1945-1953.
13. National Institute of Neurological Disorders and Stroke ad Hoc Committee. Classification of cerebrovascular diseases III. Stroke 1990;21:637-676.
14. Adams HP Jr, Bendixen BH, Kappelle LJ, et al, and the TOAST Investigators. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. Stroke 1993;24:35-41.
15. Kalra L, Yu G, Perez I, Lakhani A, Donaldson N. Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness. BMJ 2000;320:1236-1239.
16. Cabral NL, Moro C HC, Silva GR, Scola RH, Werneck LC. Unidade de AVC em Joinville: ensaio clínico randomizado. Arq Neuropsiatr 2003;61:188-193.
17. Fuster V, Ryden LE, Asinger RW, et al. ACC / AHA / ESC guidelines for the management of patients with atrial fibrillation: executive summary. J Am Coll Cardiol 2001;38:1231-1266.
18. Beyth RJ, Antani MR, Covinsky KE, et al. Why isn't warfarin prescribed to patients with nonrheumatic atrial fibrillation? J Gen Intern Med 1996;11:721-728.
19. Fitzmaurice DA. It's still not clear whether results in secondary care translate to primary care. In replly to: anticoagulation to prevent stroke atrial fibrilation BMJ 2000;321:1156.
20. Chang HJ, Bell JR, Devoo KJW, Wasson JH. Physician variation in anticoagulation patients. Arch Intern Med, 1990;150:81-84.
21. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: Incidence and prediction by factors know at the start of outpatient therapy. The Am J Med, 1989;87:144-152.
22. Wyse, DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-1833.
23. Belleli G, Bianchetti A, Trabucchi M. Let's strip the King: eligibility not safety is the problem of anticoagulation for stroke prevention in the elderly patients with atrial fibrillation. Arch Intern Med 2002;162:1067.
24. Petty GW, Brown RD Jr, Whisnant JP, et al. Frequency of major complications of aspirin, warfarin and intravenous heparin for secondary stroke prevention: a population based study. Ann Intern Med 1999;5:130:14-22.
25. Rodger H, Sudlow M, Dobson R, Kenny RA, Thonson RG. Warfarin anticoagulation in primary care: a regional survey of present practice and clinicians views Br J Gen Pract 1997:47:309-310.
26. Kutner M, Nixon G, Silverstone F. Physicians-attitudes toward oral anticoagulants and antiplatelet agents for stroke prevention in elderly patients with atrial fibrillation. Arch Intern Med 1991;151:1950-1953.
27. Secretaria Estadual de Saúde de Santa Catarina.Sem data. População estimada segundo idade e sexo.IBGE: Censo demográfico 2000.